Option chain shows key data for CCSC Technology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CCSC Technology.

CCSC Technology (NASDAQ:CCTG) Stock, Option Chain

CCSC Technology

CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.

Wall Street US stocks

Equities

Market Summary

News

Futures

Economics

Pre-Market Outlook

Markets

Trading Ideas

AMPG

CCTG

CTXR

INTZ

NVDA

TSLA

U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade.

US Stock Futures Slip After Friday&#39;s Fall: &#39;Santa Rally&#39; In Doubt? Analyst Calls It A Bit Of Profit-Taking

Things To Keep In Mind While Gifting Stocks

LUNA

CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday

Tesla's Gross Margin Shows Worst Is Behind, Creating A 'Goldilocks' Scenario For Bulls, Says Dan Ives — Elon Musk-Led EV Giant Surges Over 12% In After-Hours Trading

Movers

CARR

CNSP

DBVT

GORO

ICLR

LRHC

MNDR

ORKT

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SDRL

SVRE

VEEE

ZPTA

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

CCSC Technology International Holdings Limited - Class A Ordinary Shares

CCSC Technology International Holdings Ltd

CTCX

Carmell Shares Resumed Trade

REVB

Revelation Biosciences Shares Resumed Trade

NMRA

Neumora Therapeutics Shares Resumed Trade

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and maintains $12 price target.

Price Target

Analyst Ratings

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $12 Price Target

Carmell Shares Resumed Trade Then Again Halted Again On Circuit Breaker To The Downside, Stock Now Down 258.3%

Neumora Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up -80.6%

Revelation Biosciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down 125.6%

Cryptocurrency markets are surging on the first official trading day of 2025, with the top three coins by market capitalization up between 4% and 11% before <a href="https://www.benzinga.com/premarket">U.S. markets open</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>CRYPTOCURRENCY</td>
<td>PRICE   </td>
<td>24-HOUR GAINS +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$96,595</td>
<td>+3.4%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,462</td>
<td>+4.0%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.40</td>
<td>+10.8%</td>
</tr>
</tbody>
</table>
</figure>
What Happened: XRP has overtaken Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) to become the third-biggest cryptocurrency by market capitalization, surging to $138 billion at the time of writing.
CoinDesk on Thursday morning <a href="https://www.coindesk.com/markets/2025/01/02/xrp-rockets-11-as-bitcoin-starts-new-year-with-bullish-bang">reported</a> that XRP&#8217;s price surge coincided with an increase in trading volumes on South Korean exchanges, particularly UpBit, which saw $1.3 billion in XRP trades.
This aligns with a CoinDesk analysis from earlier in the week that highlighted unusually high XRP trading volumes from South Korean exchanges, historically a precursor to upward price volatility.
Bitcoin&#8217;s uptick has come despite the U.S. dollar having strengthened since Donald Trump&#8216;s election victory.
The DXY Index, measuring the dollar&#8217;s value against major trading partners, has risen over 3%, mirroring a pattern seen in the run-up to Trump&#8217;s first term in 2016. 
This dollar strength could potentially impact Bitcoin&#8217;s rally, as noted by Andre Dragosch, Bitwise&#8217;s head of research in Europe, who <a href="https://www.coindesk.com/markets/2025/01/02/dollars-post-election-path-is-tracking-trumps-first-presidential-term-van-straten">told</a> CoinDesk that &#8220;macro is a headwind right now.&#8221;
Industry analysts are making bold predictions, with <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42724952/2025-outlook-bitcoin-to-150000-ethereum-to-5500-dogecoin-hits-1-galaxy-research-predicts">Galaxy Research targeting a $185,000 price</a> for Bitcoin and $5,500 for Ethereum by year-end.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42745169/bitcoin-reserves-spot-etfs-ai-agents-key-trends-to-watch-in-crypto-in-2025">Bitcoin Reserves, Spot ETFs, AI Agents: Key Trends To Watch In Crypto In 2025</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$USDT

$XRP

Bitcoin, Ethereum Spike 4% While XRP Surges 11% To Become Top 3 Crypto

Truist Securities analyst William Stein reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Hold and maintains $360 price target.

Reiteration

Truist Securities Reiterates Hold on Tesla, Maintains $360 Price Target

Oppenheimer analyst Martin Yang maintains Universal Display (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NASDAQ">OLED</a>) with a Outperform and lowers the price target from $220 to $200.

OLED

Oppenheimer Maintains Outperform on Universal Display, Lowers Price Target to $200

Carmell Corporation Shares Halted On Circuit Breaker

In the current market session, RPM Intl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) share price is at $123.50, after a 0.36% spike. Moreover, over the past month, the stock fell by 11.21%, but in the past year, went up by 16.26%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1735828208_0.png" alt="Past Year Chart" />

<h3>RPM Intl P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 53.79 in the Chemicals industry, RPM Intl Inc. has a lower P/E ratio of 25.8. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1735828208_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: RPM Intl

Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) has outperformed the market over the past 15 years by 3.12% on an annualized basis producing an average annual return of 14.61%. Currently, Expedia Group has a market capitalization of $24.88 billion. 
Buying $1000 In EXPE: If an investor had bought $1000 of EXPE stock 15 years ago, it would be worth $7,663.87 today based on a price of $187.83 for EXPE at the time of writing.
<h3>Expedia Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735828208_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPE

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) saw its shares rise on Thursday following the launch of the Lucid Assistant by Lucid Group, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
This voice assistant offers Lucid Air owners a new way to control vehicle functions using only their voice, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42764010/soundhound-ai-and-lucid-motors-bring-in-vehicle-voice-assistant-with-integrated-generative-ai-to-e" rel="noreferrer noopener">according to a press release.</a>
The assistant responds to the wake words &#8220;Hey Lucid,&#8221; allowing drivers and passengers to engage in natural, conversational exchanges.
From answering real-time queries about weather, stocks, and sports, to controlling critical vehicle features like navigation, the Lucid Assistant offers an impressive range of capabilities.
Furthermore, it gives users access to the vehicle&#8217;s full manual, providing answers to almost any question about the car&#8217;s functionality.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/01/42757901/elon-musk-fireworks-or-explosive-device-caused-fatal-cybertruck-incident-at-las-vegas-trump-hotel-vehicle-was-rented" rel="noreferrer noopener">Elon Musk: Fireworks Or Explosive Device Caused Fatal Cybertruck Incident At Las Vegas Trump Hotel; Vehicle Was Rented</a>
The Lucid Assistant is powered by SoundHound&#8217;s advanced Chat AI, which integrates the latest generative AI technology, providing a seamless user experience with interactive knowledge discovery, real-time data, and intuitive in-vehicle controls.
SoundHound will showcase the Lucid Assistant at CES, where attendees can experience its functionality in the Lucid Air.
&#8220;Developing Lucid Assistant in cooperation with SoundHound enables us to deliver much more than a voice control feature,&#8221; said&nbsp;Jean-Philippe Gauthier, Head of Software Engineering at Lucid.
&#8220;In combination with Lucid&#8217;s frequent over-the-air software updates, Lucid Assistant can grow in functionality and capability over time, delivering an ever-better experience for Lucid owners.&#8221;
Lucid&#8217;s collaboration with SoundHound aims to create an evolving voice control experience that improves over time through regular software updates.
The system uses a proprietary approach, which minimizes the risk of &#8220;AI hallucinations&#8221;—misleading responses often associated with other large language models.
Currently available in English, Spanish, French, Arabic, German, and Dutch, the Lucid Assistant promises to enhance the driving experience and revolutionize how drivers interact with their vehicles.
Price Action: LCID shares are trading higher by 1.32% to $3.06 premarket at last check Thursday, while SOUN shares are trading higher by 2.92% to $20.42.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/12/42741855/elon-musks-ex-wife-and-mother-of-5-kids-says-he-wont-take-no-for-an-answer-he-locks-his-gaze-on-to-something-and-says-it-shall-be-mine?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk's Ex-Wife And Mother Of 5 Kids Says He Won't Take No For An Answer – He Locks His Gaze On To Something And Says, It Shall Be Mine</a></li>
</ul>
Photo via Shutterstock.

General

LCID

SOUN

'Hey Lucid': SoundHound AI Powers Next-Gen Voice Tech In Lucid Air

Deutsche Bank analyst Scott Deuschle maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Hold and lowers the price target from $250 to $229.

Deutsche Bank Maintains Hold on L3Harris Technologies, Lowers Price Target to $229

The new year brought little cheer for prospective U.S. homebuyers, as mortgage rates surged to their highest <a href="https://www.benzinga.com/real-estate">level in six months. </a>
The average interest rate on 30-year fixed-rate mortgages with conforming loan balances of $766,550 or less climbed to 6.97% in the week ending Dec. 27, 2024, up from 6.75% the previous week, according to data released Thursday by the Mortgage Bankers Association.
This marks the steepest rates since early July, as long-term Treasury yields remain elevated following the Federal Reserve's hawkish monetary stance. 
Notably, mortgage rates, which had trended lower for much of the first half of 2024, are now 21 basis points higher than this time last year, flipping the script on what had been a relatively friendly market for borrowers.
The surge in mortgage rates reflects broader shifts in financial markets, with long-dated Treasury yields rising alongside the Federal Open Market Committee's (FOMC) projections of fewer than-expected interest rate cuts.
<h3 class="wp-block-heading">Mortgage Applications Tumble 12.6%</h3>
With borrowing costs approaching the psychologically significant 7% threshold, mortgage activity took a nosedive. The MBA reported that mortgage applications fell 12.6% during the same week, compounding a 10.7% decline from the previous period. Seasonally adjusted, this leaves mortgage volumes at their lowest level in 10 months.
The sharp drop suggests that higher rates are squeezing demand, with many prospective buyers either unable or unwilling to lock in mortgages under such unfavorable conditions.
<h3 class="wp-block-heading">Labor Market Shows Resilience</h3>
On the flip side, labor market data offered a glimmer of optimism, as initial jobless claims fell to 211,000 in the week ending Dec. 28, down from 219,000 the previous week and beating market expectations of 222,000.
Continuing claims, which track those already receiving unemployment benefits, also dipped to 1.844 million, the lowest level since late September and below forecasts of 1.890 million. The steady decline in claims suggests that the U.S. job market remains robust in the face of rising borrowing costs.
<h3 class="wp-block-heading">Market Reactions</h3>
Thursday delivered a dose of optimism for markets as risk sentiment rebounded sharply ahead of the first trading session of the new year.
Following Tuesday&#8217;s selloff, major equity futures jumped in early trading. As of 8:40 a.m. ET, contracts on the S&amp;P 500 climbed 1%. Meanwhile, futures tied to the tech-heavy Nasdaq 100 jumped 1.2%. 
Meanwhile, the U.S. dollar index (DXY) — as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) — rose 0.3% to 108.80 levels, reaching the highest since November 2022.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42761107/us-stocks-to-open-higher-in-the-first-trading-session-of-2025-analyst-says-history-favors-rebound-after-year-end-dip">US Stocks To Open Higher In The First Trading Session Of 2025: Analyst Says History Favors Rebound After Year-End Dip</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Currency ETFs

Federal Reserve

Tech

ETFs

PowerShares DB US Dollar Index Bullish Fund

Mortgage Rates Soar To 6.97%, Applications Crash, Jobless Claims Fall: Thursday's Economic Data

On Thursday, iBio, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc.
In March, iBio collaborated with&nbsp;AstralBio to discover, engineer, and develop antibodies to treat obesity and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37959621/micro-cap-stock-ibio-doubles-on-wednesday-heres-why" rel="noreferrer noopener">other cardiometabolic conditions</a>.
The antibody, now named IBIO-600, was identified by AstralBio using iBio&#8217;s proprietary technology stack. It was designed for subcutaneous administration and has the potential for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42761297/ibio-expands-cardiometabolic-and-obesity-program-with-anti-myostatin-antibody-discovered-using-its" rel="noreferrer noopener">an extended half-life</a>.
AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio.
In addition, AstralBio will be eligible for development and commercialization milestone payments totaling up to $28 million.
If iBio sublicenses the licensed product, AstralBio will receive low to mid-single-digit sublicense fees on the proceeds of the sublicense fees.
iBio is solely responsible for the research and development, manufacturing, and commercialization activities of the licensed product.
In parallel, iBio initiated a bispecific antibody program targeting myostatin/activin A to treat obesity and cardiometabolic disorders, leveraging its proprietary Drug Discovery Platform and the technology of IBIO-600.
The myostatin licensing agreement and planned myostatin/activin A bispecific antibody program follows a drug discovery and development collaboration between iBio and AstralBio initiated less than a year ago.
iBio plans to enter into clinical investigation in obesity and cardiometabolic disorders in 2026.
In preclinical studies, IBIO-600 exhibits potent inhibition of myostatin in human muscle cell precursors, effectively blocking its inhibitory effects on muscle growth.
The company adds that IBIO-600 has been engineered to bind to the FcRn receptor with more than 10-fold higher affinity than normal IgG, supporting the potential for reduced dosing frequency.
The molecule has been advanced into non-cGMP&nbsp;in vivo studies in rodents and non-human primates, with the first data read-outs expected in early 2025.
iBio plans to use the machine-learning and epitope-steering capabilities of the Stable HU antibody optimizer with advanced mammalian display to design and produce additional multispecific antibodies targeting TGF-beta superfamily, including Myostatin and Activin A in in-vitro studies.
Price Action: At last check on Thursday, IBIO stock was up 2.04% at $2.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42764490/us-employer-health-costs-to-rise-in-2025-fueled-by-weight-loss-report">US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Contracts

IBIO

Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

DA Davidson analyst Linda Bolton Weiser maintains Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) with a Buy and maintains $16 price target.

FNKO

DA Davidson Maintains Buy on Funko, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

SGMO

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

Blade Air Mobility, NuScale Power, XTI Aerospace among industrial movers

PERI, ITRM and CADL among pre-market losers

CCSC Technology International Holdings Limited (CCTG) has released an update. CCSC Technology International Holdings Limited has appointed a new Ch...

CCSC Appoints New Chief Strategy Officer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning!



Moving stocks this morning are continued rallies, heavy trading, clinical trials and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) stock is rocketing more than 142% alongside heavy pre-market trading.</li>



<li>Mustang Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/mbio-stock-quote/">MBIO</a>) shares are soaring over 82% with strong early morning trading.</li>



<li>MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) stock is surging more than 68% as it <a href="https://investorplace.com/2024/05/why-is-mgo-global-mgol-stock-up-106-today/">continues to rally</a>.</li>



<li>Barnes &amp; Noble Education (NYSE:<a href="https://investorplace.com/stock-quotes/bned-stock-quote/">BNED</a>) shares are gaining close to 54% as its <a href="https://investorplace.com/2024/05/what-is-going-on-with-barnes-noble-education-bned-stock-today/">rally yesterday continues</a>.</li>



<li>Rezolute (NASDAQ:<a href="https://investorplace.com/stock-quotes/rzlt-stock-quote/">RZLT</a>) stock is rising over 31% after <a href="https://www.nasdaq.com/press-release/rezolute-reports-positive-topline-results-from-phase-2-proof-of-concept-study-of">releasing positive study results</a>.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are increasing more than 28% with heavy trading this morning.</li>



<li>Mangoceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrx-stock-quote/">MGRX</a>) stock is heading over 22% higher after <a href="https://investorplace.com/2024/05/why-is-mangoceuticals-mgrx-stock-up-130-today/">rallying yesterday too</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are climbing more than 19% without any clear news this morning.</li>



<li>Eupraxia Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/eprx-stock-quote/">EPRX</a>) stock is jumping over 15% on <a href="https://www.marketwatch.com/story/eupraxia-pharmaceuticals-shares-pop-after-new-trial-data-4e20f13b?mod=newsviewer_click">new drug trial data</a>.</li>



<li>CCSC Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctg-stock-quote/">CCTG</a>) shares are up more than 15% despite a lack of news.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Crown ElectroKinetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crkn-stock-quote/">CRKN</a>) stock is diving over 24% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318339015&amp;type=PDF&amp;symbol=CRKN&amp;cdn=9fd92bcd34f4f2180730286b7103ecb0&amp;companyName=Crown+Electrokinetics+Corp.&amp;formType=DEF+14A&amp;formDescription=Other+definitive+proxy+statements&amp;dateFiled=2024-05-21">announcing shareholder meeting plans</a>.</li>



<li>Edible Garden (NASDAQ:<a href="https://investorplace.com/stock-quotes/edbl-stock-quote/">EDBL</a>) shares are tumbling more than 24% without any apparent news to report.</li>



<li>Euronav (NYSE:<a href="https://investorplace.com/stock-quotes/eurn-stock-quote/">EURN</a>) stock is taking an over 20% beating on no clear news this morning.</li>



<li>Sintx Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sint-stock-quote/">SINT</a>) shares are sliding nearly 19% on Wednesday morning.</li>



<li>FLJ Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/flj-stock-quote/">FLJ</a>) stock is dropping more than 16% this morning.</li>



<li>Cheetah Net Supply Chain (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctnt-stock-quote/">CTNT</a>) shares are falling over 16% as they continue to drop.</li>



<li>LifeStance Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/lfst-stock-quote/">LFST</a>) stock is decreasing more than 15% after <a href="https://www.nasdaq.com/press-release/lifestance-health-group-announces-pricing-of-secondary-public-offering-2024-05-21">pricing a secondary offering</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) shares are dipping over 15% after rallying yesterday.</li>



<li>Meta Data (NYSE:<a href="https://investorplace.com/stock-quotes/aiu-stock-quote/">AIU</a>) stock is slipping more than 15% today.</li>



<li>Vicarious Surgical (NYSE:<a href="https://investorplace.com/stock-quotes/rbot-stock-quote/">RBOT</a>) shares close out our pre-market stock movers down over 14% on a <a href="https://www.investing.com/news/company-news/vicarious-surgical-ceo-sells-shares-worth-9506-93CH-3450561">CEO share sale</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-may-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Greenwave Technology, FREYR Battery, Golden Ocean among industrial movers

IPO Roundup: Ardent Health, TWFG, Artiva Biotherapeutics, and more

CCSC Technology International Holdings GAAP EPS of -$0.13, revenue of $14.7M

CCSC Technology International Holdings Limited (CCTG) has released an update. CCSC Technology International Holdings Limited has announced its Annu...

CCSC Technology International's Key AGM Proposals

CCSC Technology International Holdings Limited (CCTG) has released an update. CCSC Technology International Holdings Limited recently convened its ...

CCSC Technology Shareholders Approve Key Resolutions

CCSC Technology International Holdings Limited ( ($CCTG) ) has provided an update. CCSC Technology International Holdings Limited reported its unau...

CCSC Technology Reports Increased Revenue but Higher Operational Losses for 2024

ACTU

ADIL

AKTS

ALUR

ARDT

ARTV

BACQU

BLMZ

BNED

BRTX

BTOG

CADL

CJET

CRKN

CTNT

DATS

DMTK

EDBL

EPRX

EURN

FLAI

FLGC

HUBC

IAUX

ITRM

KSPI

LFST

LPAAU

LRTX

MBIO

MDIA

MGOL

MGRX

PERI

PGHL

RBOT

RZLT

SERV

SGLY

SINT

SOAR

SPIR

TWFG

VRME

VSME

VVPR

XXII

ZCMD

ZOOZ

Small Cap

Opinion

Press Releases

Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?

CCSC Technology International Holdings Limited Appoints Jung Yi Chiu as Chief Strategy Officer

CCSC Technology International Holdings Limited Announces Plan for New Supply Chain Management Center in Central Europe

New European Supply Chain Center to Enhance Global Growth of Interconnected Products Needed in a Wide Range of Industries: CCSC Technology International Holdings Limited (Nasdaq: CCTG)

CCSC Technology International Holdings Limited Enters into Strategic Cooperation Framework Agreement with Innogetic International Limited

CCSC Technology International Holdings Limited Enters into International Purchase Agreement with SHI / LIGHTCARE-SOLUTIONS ApS

New International Agreements for AI Applications and Healthcare Lighting, Plus Plans for European Supply Chain Center to Serve Varied Tech Industries: CCSC Technology (Nasdaq: CCTG)

Earnings

CCSC Technology International Holdings Limited Reports Financial Results for Fiscal Year 2024

Early Movers: PRSO, TVGN, ZENA, CCTG, CRDL Stocks to Watch Today!

Commodities

CCSC Technology International Holdings Limited Reports Financial Results for the First Six Months of Fiscal Year 2025 Ended September 30, 2024

Comments

CCSC Technology

CCSC Technology (CCTG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga